AAAAAA

   
Results: 1-11 |
Results: 11
A COMPARATIVE-ANALYSIS OF SURVEYORS FROM 6 HOSPITAL ACCREDITATION PROGRAMS AND A CONSIDERATION OF THE RELATED MANAGEMENT ISSUES
Authors: BOHIGAS L BROOKS T DONAHUE T DONALDSON B HEIDEMANN E SHAW C SMITH D
Citation: L. Bohigas et al., A COMPARATIVE-ANALYSIS OF SURVEYORS FROM 6 HOSPITAL ACCREDITATION PROGRAMS AND A CONSIDERATION OF THE RELATED MANAGEMENT ISSUES, International journal for quality in health care, 10(1), 1998, pp. 7-13
RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL CHEMOTHERAPY ADDED TO TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH NODE-POSITIVE ESTROGEN AND OR PROGESTERONE RECEPTOR-POSITIVE BREAST-CANCER/
Authors: HEIDEMANN E
Citation: E. Heidemann, RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL CHEMOTHERAPY ADDED TO TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH NODE-POSITIVE ESTROGEN AND OR PROGESTERONE RECEPTOR-POSITIVE BREAST-CANCER/, Strahlentherapie und Onkologie, 174(5), 1998, pp. 290-291
MITOXANTRONE (N) VS. 5-FLUOROURACIL EPIRUBICIN/CYCLOPHOSPHAMIDE (FEC)AS FIRST LINE THERAPY IN HIGH-RISK METASTATIC BREAST-CANCER/
Authors: VONMINCKWITZ G HEIDEMANN E SOUCHON R SAMONIGG H HIRSCHMANN WD BODENSTEIN H SCHINDLER A SCHULZE M CLEMENS H KONIG M SCHARL A FISCHER JT KAUFMANN M
Citation: G. Vonminckwitz et al., MITOXANTRONE (N) VS. 5-FLUOROURACIL EPIRUBICIN/CYCLOPHOSPHAMIDE (FEC)AS FIRST LINE THERAPY IN HIGH-RISK METASTATIC BREAST-CANCER/, European journal of cancer, 33, 1997, pp. 646-646
ACCREDITATION PROGRAMS FOR HOSPITALS - FUNDING AND OPERATION
Authors: BOHIGAS L SMITH D BROOKS T DONAHUE T HEIDEMANN E DONALDSON B SHAW C
Citation: L. Bohigas et al., ACCREDITATION PROGRAMS FOR HOSPITALS - FUNDING AND OPERATION, International journal for quality in health care, 8(6), 1996, pp. 583-589
LEVAMISOLE AND 5-FLUOROURACIL AS AN ADJUVANT THERAPY FOR PATIENTS AFTER CURATIVE RESECTION OF COLON-CARCINOMA DUKES STAGE-C (TNM-III) - MORE DISADVANTAGES THAN ADVANTAGES
Authors: WASSNER A HEIDEMANN E
Citation: A. Wassner et E. Heidemann, LEVAMISOLE AND 5-FLUOROURACIL AS AN ADJUVANT THERAPY FOR PATIENTS AFTER CURATIVE RESECTION OF COLON-CARCINOMA DUKES STAGE-C (TNM-III) - MORE DISADVANTAGES THAN ADVANTAGES, Onkologie, 19(2), 1996, pp. 140-145
IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS
Authors: GRAMATZKI M REPP R DIEHL S STROBEL G WANDT H LOFFLER B BODENSTEIN H SCHONROCK P SCHLIMOK G HEIDEMANN E OTREMBA B OHL S SCHNEIDER C EHNINGER G LINK H
Citation: M. Gramatzki et al., IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS, Blood, 88(10), 1996, pp. 2230-2230
ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH HIGH-DOSE ARA-C POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA
Authors: LINK H EHNINGER G",SCHONROCKNABULSI,GRAMATZKI,"FRANKE A EINSELE H TISCHLER J BRACK N OTREMBA B LUTZ M GACKLE R OHL S HEIDEMANN E WILHELM M LOFFLER B WEISS J GEER T DIEHL S WANDT H
Citation: H. Link et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION COMPARED WITH HIGH-DOSE ARA-C POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA, Blood, 88(10), 1996, pp. 2723-2723
UNTITLED
Authors: SCRIVENS E HEIDEMANN E
Citation: E. Scrivens et E. Heidemann, UNTITLED, The International journal of health planning and management, 10(3), 1995, pp. 161-164
DEVELOPMENT OF AN EXTRAMEDULLARY BLAST CR ISIS AND MEGAKARYOCYTIC LEUKEMIA
Authors: JACOB A KREFT A GEORGII A HEIDEMANN E
Citation: A. Jacob et al., DEVELOPMENT OF AN EXTRAMEDULLARY BLAST CR ISIS AND MEGAKARYOCYTIC LEUKEMIA, Onkologie, 18(1), 1995, pp. 93-93
PROGNOSTIC SUBGROUPS - THE KEY FACTOR FOR TREATMENT OUTCOME IN METASTATIC BREAST-CANCER - RESULTS OF A 3-ARM RANDOMIZED MULTICENTER TRIAL COMPARING DOXORUBICIN, EPIRUBICIN AND MITOXANTRONE EACH IN COMBINATION WITH CYCLOPHOSPHAMIDE
Authors: HEIDEMANN E STEINKE B HARTLAPP J SCHUMACHER K POSSINGER K KUNZ S NEESER E VONINGERSLEBEN G HOSSFELD D CAFFIER H SOUCHON R WALDMANN R BLUMNER E CLARK J
Citation: E. Heidemann et al., PROGNOSTIC SUBGROUPS - THE KEY FACTOR FOR TREATMENT OUTCOME IN METASTATIC BREAST-CANCER - RESULTS OF A 3-ARM RANDOMIZED MULTICENTER TRIAL COMPARING DOXORUBICIN, EPIRUBICIN AND MITOXANTRONE EACH IN COMBINATION WITH CYCLOPHOSPHAMIDE, Onkologie, 16(5), 1993, pp. 344-353
TOPICALLY APPLIED MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH SKIN-METASTASIZED BREAST-CANCER - A PHASE-II STUDY
Authors: UNGER C HERRMANN R BERDEL WE KLEEBERG UR GATZEMEIER U ILLIGER HJ WANDER HE WESTERHAUSEN M BECHER R BREMER K RIECHE K ESSERS U QUEISSER W HEIDEMANN E FIEBIG HH POSSINGER K JOURDAINMADL B HEIM ME EDLER L
Citation: C. Unger et al., TOPICALLY APPLIED MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN PATIENTS WITH SKIN-METASTASIZED BREAST-CANCER - A PHASE-II STUDY, Onkologie, 16(3), 1993, pp. 170-173
Risultati: 1-11 |